The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis.
Evidence is presented that rheumatoid arthritis is a disease resulting from abnormal protein binding and that anti-rheumatic drugs act by correcting the abnormal binding.
D000893:Anti-Inflammatory Agents / Q000097:blood* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D001667:Binding, Competitive; D001798:Blood Proteins / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D011485:Protein Binding; D012459:Salicylates / Q000097:blood; D012709:Serum Albumin / Q000378:metabolism; D014364:Tryptophan / Q000097:blood
D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D012459:Salicylates; D012709:Serum Albumin; D014364:Tryptophan